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in length and they may have to be edited for publication. 
Regarding "What you didn't know about the 
NASCET" 
To the Editors: 
As a member of the Data Monitoring Committee of the 
North American Symptomatic Carotid Endarterectomy 
Trial (NASCET), as mentioned by Dr. D. Eugene Strand- 
ness in his commentary (J VAse Suv, c 1995;25:163-5), I 
feel constrained to offer my own comments in the light of 
the references to my role in the committee. 
I was keenly aware of the reports of a number of my 
vascular surgery colleagues, whose opinions I respected and 
whose conclusions confirmed those that I had reached 
based on my own experience- namely, that severe carotid 
artery stenosis corrected by surgical intervention with a 
sufficiently low operative complication rate results in 
relative protection from future stroke. So, armed with a 
background of  experience with randomized clinical trials 
and sustained by personal experience with more than 1500 
surgical patients, I accepted the invitation to join the data 
monitoring committee of NASCET. Although I had 
personal reservations about contributing patients, I felt that 
I might lend credibility to the outcome of the study, 
whatever it might be. 
There appeared to be an adversarial relationship be- 
tween the principal investigator and the data monitoring 
committee. When the difficult and pointed questions that 
need to be asked during any clinical trial were asked, they 
were often met with a defensive posture by the principal 
investigator. This impression appears to be confirmed by 
the correspondence that Dr. Barnett had with Dr. Michael 
Walker, cited by Dr. Strandness. To the credit of Dr. 
Walker and the NIH group, when I asked for an emergency 
meeting when the favorable results of surgical intervention 
for severe carotid stenoses became apparent, o consider the 
question of what was to be done with patients who were 
entered into the middle moderate stenosis group and who 
had proceeded to preocclusive stenosis, the meeting was 
held. 
For the data monitoring committee to be effective and 
contribute to the acceptance of the results, very pointed 
questions must be raised during its deliberations. Such 
questions now almost inevitably introduce adversarial 
positions and animosities. In essence, how to organize 
prospective, randomized clinical trials needs to be reevalu- 
ated so that they cease to be vehicles for career advancement 
and so that repetition and reduplication become unneces- 
sary, because it is our patients who suffer in these trials. Not 
only do they suffer because of the need to weigh conflicting 
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evidence presented by physicians who have vested interests 
in the outcome of the trials and who must adopt dual, often 
conflicting, roles-compassionate physician versus dispas- 
sionate, coldly objective investigator-but also because 
they may surrender their rights to meaningful treatment. It
does no good to invoke the greater good that will result 
from the studies if a trial turns out to be inconclusive 
because of procedural problems, conceptual deficiencies, or 
personality conflicts. Shouldn't the recruitment of  the pa- 
tients be performed by nonparticipants of the studies who 
have no vested interest in the outcome? These are issues 
that are at the heart of the comments offered by Dr. Strand- 
ness, issues that could jeopardize the acceptance ofany large 
clinical trial. I agree with Dr. Strandness that the data 
monitoring committee should be privy to the data in an 
ongoing fashion, but as long as the investigators feel that 
they are the "owners" of the trial and of the data, and as 
long as th e protocols are flawed from the start, how can a 
data monitoring committee be as effective as it might? 
The NASCET has made a great contribution in 
preventing strokes, albeit with a higher than desirable or 
achievable surgical complication rate,* by helping to 
validate the voluminous evidence regarding the efficacy of 
carotid endarterectomy for advanced carotid disease de- 
tected by measuring the degree of carotid stenosis with 
angiography. It still leaves us with the fundamental nd 
much debated questions, "What is the validity of measuring 
carotid stenosis on an angiogram, by whatever technique, 
as the sole criterion for undertaking carotid endarterec- 
tomy? How should it be measured? 2,3 Wouldn't the 
flow/velocity studies emphasized by Gene Strandness have 
helped to at least clarify quantification of stenosis when 
combined with angiography?" The futility of attempting to 
differentiate between 79% stenoses and 81% stenoses is 
obvious, if by no other data than the inability to precisely 
equate stenoses measured in the European Carotid End- 
arterectomy TriaP and NASCET, whose clinical outcomes 
were nevertheless identical. It was realized before either 
trial was begun that the critical factfir of carotid plaques in 
causing strokes was plaque composition. Yet bq.th studies 
failed to deal with these data. 
Anthony M. Imparato, MD 
Division of Vascular Surgery 
New York Medical Center 
550 First Avenue, Suite 6F 
New York, NY 10016 
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Regarding %Vhat you didn't  know about the 
NASCET" 
To the Editors: 
In a recent editorial (J VASC SURG 1995;25:163-5), 
Dr. Eugene Strandness raised several concerns about the 
data monitoring committee of the North American Symp- 
tomatic Carotid Endarterectomy Trial (NASCET). Be- 
cause of the importance of the trial and the seriousness of 
the concerns, I asked a group of four consultants (one from 
the National Heart, Lung, and Blood Institute and three 
from outside of the National Institutes of Health) to meet 
and review the procedures used by the National Institute of 
Neurological Disorders and Stroke (NINDS) in organiz- 
ing and guiding the monitoring committee for NASCET. 
The consultants looked specifically at the question of 
whether the results of the trial were jeopardized because of 
the issues raised by Dr. Strandness, and found that they 
were not. They also found no evidence of misconduct by 
the NINDS staff. The consultants emphasized, however, 
that several aspects of the way that the data monitoring 
committee for NASCET has been operated could be 
improved, and suggested that NINDS review the proce- 
dures by which we organize and guide data- and safety- 
monitoring committees. As a result, NINDS is now 
formulating a new set of guidelines for these procedures. 
These guidelines will be made available to the research 
community when they are completed. We are grateful to 
Dr. Strandness for raising these issues and hope that we will 
be able to serve the clinical research community even more 
effectively as a result of these changes. 
Zach W. Hall, PhD 
National Institute of Neurological Disorders and Stroke 
Bldg. 31, Rm. 8A52 
Bethesda, MD 20892 
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Editors" Comments 
These two letters conclude what has been perceived as 
a very vexing problem that faces investigators participating 
in clinical research initiatives that involve patients with 
vascular diseases. The Editors particularly appreciate Dr. 
Hall's response, which notes that NINDS is "formulating 
a new set of guidelines" to address the concerns that Dr. 
Strandness expressed in his special communication i the 
January 1995 issue of the Journal of Vascular Surgery. 
Calvin B. Ernst, MD 
James C. Stanley, MD 
Editors 
